TargetMol

BIBR 1532

Product Code:
 
TAR-T2380
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T2380-1mL1 mL * 10 mM (in DMSO)£107.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2380-5mg5mg£107.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2380-10mg10mg£136.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2380-25mg25mg£189.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2380-50mg50mg£283.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2380-100mg100mg£455.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2380-500mg500mg£938.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
BIBR 1532 is an effective, specific and non-competitive telomerase inhibitor (IC50: 100 nM, in a cell-free assay).
CAS:
321674-73-1
Formula:
C21H17NO3
Molecular Weight:
331.371
Pathway:
Apoptosis; DNA Damage/DNA Repair
Purity:
0.9955
SMILES:
CC(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1
Target:
Apoptosis; Telomerase

References

1. Pascolo E, et al. J Biol Chem. 2002, 277(18), 15566-15572. 2. El-Daly H, et al. Blood. 2005, 105(4), 1742-1749. 3. Ward RJ, et al. Mol Pharmacol. 2005, 68(3), 779-786. 4. R?th A, et al. Leukemia. 2007, 21(12), 2456-2462. 5. Meng E, et al. Gynecol Oncol. 2012, 124(3), 598-605.